Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema

BACKGROUND/AIMS: The RELIGHT clinical trial used an individualised treatment regimen of ranibizumab to treat diabetic macular oedema (DMO). We report findings from two patient-reported outcome instruments. METHODS: The National Eye Institute Visual Function Questionnaire (NEI-VFQ) was administered b...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ Open Ophthalmol
Päätekijät: Chakravarthy, Usha, Pearce, Ian, Banerjee, Sanjiv, Burton, Benjamin J L, Downey, Louise, Gale, Richard, Patel, Jignesh, Patra, Sudeshna, Sivaprasad, Sobha, Stevenson, Michael, Lupton, Susanne
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2019
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6528749/
https://ncbi.nlm.nih.gov/pubmed/31179389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjophth-2018-000226
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia